The 340B Drug Pricing Program “has enabled hospitals and health systems to support and expand access and services consistent with their mission and the program’s original and ongoing charge,” the AHA and Association of American Medical Colleges today told leaders of the House Energy and Commerce Committee and its Subcommittee on Oversight and Investigations. In the letter, AHA and AAMC provided examples of how hospitals and health systems have used 340B savings to expand access and services. These include supporting neonatal intensive care units and training for physicians to care for vulnerable newborns; providing low-income patients with free outpatient drugs; and pharmacist counseling services for medication therapy disease management, including telephone consultations for outpatients with conditions such as diabetes, hypertension and asthma. The letter also notes that the 340B program is not federally funded, and 340B sales are less than 3% of the total U.S. drug market. The Oversight and Investigations Subcommittee will hold a hearing on the 340B program Oct. 11.

Related News Articles

Blog
In this AHA Stat Blog, the AHA’s Jay Bhatt, senior vice president and chief medical officer, and Melissa Mannon, associate director of policy development,…
Headline
The Centers for Medicare…
Blog
AHA staff recently visited two rural hospitals to see and hear firsthand how leaders are engaging in innovative practices to increase accessibility and…
Headline
The Centers for Medicare…
Headline
Tax-exempt hospitals in the 340B drug savings program provided $56.1 billion in total benefits to their communities in 2016, the most recent year for which…
Headline
The Centers for Medicare…